-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NHjhISFwW5f6T+lRQEw2ckj2NXKjtJdNJBOaQPTZvxzYJi0Xs7rRF5NOjJSC8Pbe wyRPG+dOEQHtLAcKZFU+pQ== 0000950123-05-011720.txt : 20050930 0000950123-05-011720.hdr.sgml : 20050930 20050930154458 ACCESSION NUMBER: 0000950123-05-011720 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050930 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050930 DATE AS OF CHANGE: 20050930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CAMBREX CORP CENTRAL INDEX KEY: 0000820081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222476135 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10638 FILM NUMBER: 051114182 BUSINESS ADDRESS: STREET 1: ONE MEADOWLANDS PLZ CITY: E RUTHERFORD STATE: NJ ZIP: 07073 BUSINESS PHONE: 2018043000 MAIL ADDRESS: STREET 1: ONE MEADOWLANDS PLAZA CITY: E. RUTHERFORD STATE: NJ ZIP: 07073 8-K 1 y13277e8vk.txt FORM 8-K CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2005 ------------------------- CAMBREX CORPORATION - ------------------------------------------------------------------------------- (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 - ------------------------------------------------------------------------------- (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.) ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY 07073 - ------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (201) 804-3000 ------------------------ Check the appropriate box if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(d) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) CAMBREX CORPORATION Form 8-K Current Report September 30, 2005 Section 5 - Corporate Governance and Management Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (1) 5.02(b) Cambrex Corporation is reporting under Item 5.02(b) that on September 26, 2005, N. David Eansor, President, Cambrex Bioproducts, resigned to pursue other interests. On September 30, 2005, Cambrex Corporation issued a press release announcing Mr. Eansor's resignation. (2) 5.02(c) Cambrex Corporation is reporting under Item 5.02(c) that effective September 30, 2005, Cambrex appointed Shawn P. Cavanaugh, Senior Vice President and General Manager, Cambrex Bioproducts to replace N. David Eansor. On September 30, 2005, Cambrex Corporation issued a press release announcing the appointment of Mr. Cavanaugh. Mr. Cavanagh joined Cambrex in October 1999 with the acquisition of FMC BioProducts. Thereafter, Mr. Cavanaugh held various positions with Cambrex subsidiaries. In 2000, he was promoted to the position of Global Director, Endotoxin Detection and in 2004 to the position of Vice President, Cambrex Bioproducts. Prior to joining Cambrex, Mr. Cavanagh held various Management and Engineering positions with FMC BioProducts and Eveready Battery Company from 1988 to 1999. Item 9.01 - Financial Statements and Exhibits (c) Exhibits (99.1) Press release issued by Cambrex Corporation dated September 30, 2005. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized. CAMBREX CORPORATION Date: September 30, 2005 By: /s/ Peter E. Thauer -------------------- -------------------------- Name: Peter E. Thauer Title: Senior Vice President, General Counsel and Corporate Secretary Exhibit 99.1 Cambrex Corporation Press release dated September 30, 2005. EX-99.1 2 y13277exv99w1.txt PRESS RELEASE [CAMBREX LOGO] News Release Date: September 30, 2005 Contact: Anne-Marie Hess Director, Investor Relations & Corporate Communications Phone: 201-804-3062 Email: annemarie.hess@cambrex.com -------------------------- Release: Immediate SHAWN P. CAVANAGH IS APPOINTED SENIOR VICE PRESIDENT AND GENERAL ---------------------------------------------------------------- MANAGER, CAMBREX BIOPRODUCTS ---------------------------- East Rutherford, NJ - September 30, 2005 - Cambrex Corporation (NYSE: CBM) announces today that Shawn P. Cavanagh has been appointed Senior Vice President and General Manager, Cambrex Bioproducts and that N. David Eansor, formerly head of Bioproducts, has resigned to pursue other interests. Mr. Cavanagh joined Cambrex in October 1999 with the acquisition of FMC BioProducts. In 2000, he was promoted to the position Global Director, Endotoxin Detection, and in 2004, to the position of Vice President, Bioproducts. Performance of the businesses that Mr. Cavanagh has been responsible for has been very strong over the last five years and most recently he led the effort to acquire Genolife and associated rapid microbial detection technologies. Prior to joining Cambrex, Mr. Cavanagh held various management and engineering positions with FMC BioProducts. "Shawn is an integral part of the Bioproducts leadership team and has the experience, breadth of knowledge and talent to seamlessly assume the leadership role of the Bioproducts business," commented John R. Leone, President and Chief Executive Officer. "Under Shawn's leadership, we are confident that the outstanding growth of this strategic business will continue into the future." "We are very appreciative of Dave Eansor's efforts. He was instrumental in building the Bioproducts business, forming an outstanding leadership team and developing a portfolio of technologies on which we will build upon in the future," Mr. Leone continued. Cambrex Corporation | One Meadowlands Plaza | East Rutherford, NJ 07073 Phone 201.804.3000 | Fax 201.804.9852 | www.cambrex.com About Cambrex - ------------- Cambrex is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit www.cambrex.com. --------------- # # # -----END PRIVACY-ENHANCED MESSAGE-----